Fferent Pulp Dressing Materials For The Pulpotomy: Di of Primary Teeth: A Systematic Review of The Literature
Fferent Pulp Dressing Materials For The Pulpotomy: Di of Primary Teeth: A Systematic Review of The Literature
Fferent Pulp Dressing Materials For The Pulpotomy: Di of Primary Teeth: A Systematic Review of The Literature
Clinical Medicine
Review
Different Pulp Dressing Materials for the Pulpotomy
of Primary Teeth: A Systematic Review of
the Literature
Maurizio Bossù 1,† , Flavia Iaculli 2,† , Gianni Di Giorgio 2, *, Alessandro Salucci 1 ,
Antonella Polimeni 1 and Stefano Di Carlo 1
1 Department of Oral and Maxillofacial Science, “Sapienza” University of Rome, 00185 Rome, Italy;
[email protected] (M.B.); [email protected] (A.S.);
[email protected] (A.P.); [email protected] (S.D.C.)
2 Pediatric Dentistry School, Department of Oral and Maxillofacial Science, “Sapienza” University of Rome,
00185 Rome, Italy; [email protected]
* Correspondence: [email protected]; Tel.: +39-349-547-7903
† These Authors contributed equally to this work.
Received: 27 January 2020; Accepted: 16 March 2020; Published: 19 March 2020
Abstract: Background: Pulpotomy of primary teeth provides favorable clinical results over time;
however, to date, there is still not a consensus on an ideal pulp dressing material. Therefore, the
aim of the present systematic review was to compare pulpotomy agents to establish a preferred
material to use. Methods: After raising a PICO question, the PRISMA guideline was adopted to carry
out an electronic search through the MEDLINE database to identify comparative studies on several
pulp dressing agents, published up to October 2019. Results: The search resulted in 4274 records;
after exclusion, a total of 41 papers were included in the present review. Mineral trioxide aggregate
(MTA), Biodentine and ferric sulphate yielded good clinical results over time and might be safely
used in the pulpotomies of primary molars. Among agents, MTA seemed to be the material of choice.
On the contrary, calcium hydroxide showed the worst clinical performance. Although clinically
successful, formocreosol should be replaced by other materials, due to its potential cytotoxicity and
carcinogenicity. Conclusion: MTA seemed to be the gold standard material in the pulpotomy of
primary teeth. Promising results were also provided by calcium silicate-based cements. Further
randomized clinical trials (RCTs) with adequate sample sizes and long follow-ups are encouraged to
support these outcomes.
Keywords: biodentine; calcium hydroxide; ferric sulphate; MTA; primary teeth; pulpotomy
1. Introduction
Dental caries is an infective, chronic, degenerative and multifactorial condition that represents
the most prevalent chronic disease worldwide, mainly in children [1,2]. Tooth decay would seem to
be one of the major public health problems related not only to primary teeth but also to permanent
ones, and, despite the preventive strategies mostly adopted in developed countries, 2.4 billion adults
and 486 million children are affected by dental decay in the permanent and deciduous dentition,
respectively [3].
Early caries management should avoid the progressive destruction of dental hard tissue and
subsequent loss of dental vitality [4], inducing critical conditions in which premature tooth extraction
is required [5]. This is mostly true for primary teeth (due to anatomical considerations, reduced
rate of mineralization and high prevalence of risk factors) that show a rapid progression of tooth
decay [2,4,6]. Therefore, vital pulp therapy (VPT) has been proposed to preserve the pulp vitality of
deciduous or young permanent teeth with immature roots affected by caries and without evidence
of radicular pathology [7,8]. Nowadays, treatment options of VPT are represented by indirect pulp
treatment (namely indirect pulp capping), direct pulp capping and pulpotomy [7]. Although clinically
successful in primary molars, direct capping is mainly recommended in the VPT of permanent young
teeth [9,10] and indirect capping seems to possess a relative effectiveness when compared to pulpotomy
procedures [11]. The latter provides favorable clinical survival rates over time and allows the vitality
of primary teeth until their natural exfoliation, avoiding pulpectomy procedures [2]. Pulpotomy
consists of elimination of the bacterial infection by the removal of the pulp in the pulp chamber; then,
the decontaminated tooth is filled with a medicament [11]. The most frequently used agents are
mineral trioxide aggregate (MTA), Biodentine (BD), formocresol (FC), ferric sulphate (FS) and calcium
hydroxide (CH). When compared, FC, FS and MTA seemed to provide significantly better clinical
and radiographic results as pulpotomy agents than CH after two years of follow-up; moreover, MTA
showed the best performance in respect to FC and FS over time [12]. Accordingly, Stringhini et al. [13]
reported that MTA yielded superior clinical and radiographical results in comparison to FC. On the
other hand, electrosurgery and FS showed similar success to FC, whereas CH did not show positive
evidence as medicament in pulpotomies of primary teeth [13]. In the same way, Asgary et al. [14]
further stressed that MTA demonstrated better long-term outcomes in pulpotomy of primary molars
when compared with FS.
More recently, bioactive endodontic cements have been introduced as valid alternatives to MTA in
VPT, showing promising clinical results [15]. In addition, calcium-silicate-based cement demonstrates
no difference when compared to MTA in the pulpotomies of primary teeth [4]; however, further
long-term studies with larger sample sizes are needed to confirm these preliminary outcomes.
To date there is still not an ideal pulp dressing material to be used in the pulpotomy of primary
teeth. Therefore, the aim of the present systematic review was to compare several pulpotomy agents in
order to establish a preferred material that performs better than others.
After removing the duplicates, some papers were excluded subsequent to reading of the titles.
Two review authors (F.I., G.D.G.) independently screened the selected abstracts to identify relevant
studies according to the inclusion/exclusion criteria. In case of disagreement, a Senior Author (M.B.)
was consulted and agreement was reached. Then, full reports of the selected studies were retrieved
and a data extraction form was completed for each paper in an unblinded standardized manner, to
determine whether the article should be included or excluded. Excluded studies and reasons for
exclusion were reported.
• Pulpotomy procedure
• Materials management
• Expertise of the clinician
• Restoration materials
• Outcome variables
bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias),
selective reporting (reporting bias), or other possible causes of bias.
Assessment of overall risk of bias was classified as follows: low risk of bias if all criteria were met;
unclear risk of bias if one or more criteria were assessed as unclear; or high risk of bias if one or more
criteria were not met [2].
3. Results
Flowchartofofthe
Figure1.1.Flowchart
Figure thereview
reviewprocess
processand
andsearch
searchstrategy
strategyaccording
accordingtotoPRISMA
PRISMAstatement.
statement.
Concerning materials management, the included studies evaluated several materials (e.g., MTA,
BD, FS, CH, FC) that were applied with almost with the same procedure according to the manufacturer’s
instructions; however, it should be considered that they were produced by various companies and might
have a slightly different composition. Accordingly, the restoration materials reported by the included
studies were different (composite, amalgam, glass ionomer cement, stainless steel crowns), however, in
order to avoid bias, papers reporting teeth restored with temporary materials were excluded. Regarding
the evaluated outcomes, all of the included studies assessed clinical and radiographical parameters;
the success criteria used among the articles were similar but not the same and, therefore, it was only
possible to make a descriptive comparison between the papers. Finally, the clinician expertise could
not be evaluated in each study and the follow-up range varied between 12 and 42 months. Therefore,
due to the lack of unequivocal data presentation, the results of the studies were reported separately.
Noorollahian 2008
Low Unclear High Low High Low
[75]
Figure2.2.Overall
Figure Overallrisk
riskof
ofbias.
bias.
3.4. Outcomes
Data and results reported by each of the included studies are summarized in Table 3.
J. Clin. Med. 2020, 9, 838 7 of 23
Table 3. Summary of the data reported in the studies included in the present systematic review.
Table 3. Cont.
Table 3. Cont.
Table 3. Cont.
Table 3. Cont.
Table 3. Cont.
Table 3. Cont.
Absence of
spontaneous or
Absence of furcal or
severe pain, Comparable success was
amalgam (in case of periapical radiolucency, At the end of 24 months, the
DFC group (n = 15) pathological achieved using ABS, FC
Ozmen et al. DFC vs. ABS Class I cavities) or SCC widened periodontal clinical success rates for ABS, RX success: DFC 80%,
ABS group (n = 15) 24 months mobility, swelling, and FS as pulpotomy
2017 [83] vs. FS**** (in case of Class II ligament spaces, internal or DFC and FS were 87%, 87% ABS 87%, FS 87%.
FS group (n = 15) sinus tract, agents of deciduous teeth.
cavities) external root resorption, loss and 100%, respectively.
tenderness to
of lamina dura.
percussion,
palpation.
Absence of internal root
Comparable results were
NaOCl group Absence of pain, resorption, furcation 18 months: rx success
NaOCl vs. 18 months: the clinical success obtained using NaOCl,
Farsi et al. (n = 27) ZOE and SCC cemented 12 and swelling, sinus tract, radiolucency, periapical rates were NaOCl 91.7%,
DFC vs. FS rates were NaOCl 83.3%, FC DFC and FS as
2015 [84] DFC group (n = 27) with GIC. 18 months mobility, pain on radiolucency, widening of FC 100%, FS 91.3%,
(not specified) 96%, FS 87%, respectively. pulpotomy agents for
FS group (n = 27) percussion. the periodontal ligament respectively.
primary molars.
space.
Absence of history
of pain, tenderness
to Absence of integrity of
MTA success rate was
MTA group palpation/percussion, lamina, radiolucencies in the MTA success rate was 100% in MTA provided promising
Jayam et al. white MTA** SCC and/or GI and 100% in comparison to
(n = 50) 24 months pathological apical or bifurcation areas of comparison to 90.48% success results as pulpotomy
2014 [85] vs. FC◦◦◦◦ amalgam. 90.48% success in FC
FC group (n = 50) mobility, intra- or tooth, pathological internal in FC group. dressing material.
group.
extra-oral swelling, or external root resorption.
intra- or extra-oral
sinus.
Absence of After 12 months, DFC clinical
Absence of abnormal root
spontaneous pain, success rate was 91.3%. In the Radiographic success MTA seemed to be
MTA group resorption, internal root
Srinivasan et al. MTA** vs. draining fistula, MTA group, no clinical signs rates were 78.26% and clinically and
(n = 50) SSC 12 months resorption, furcation
2011 [86] DFC swelling or abscess, and symptoms were noted; 95.74%, in DFC and MTA radiographically superior
DFC group (n = 50) involvement, periapical bone
mobility, premature thus, the clinical success was group, respectively. to FC.
destruction.
exfoliation, 100%.
BD and DFC pulpotomy
Absence of pain, The BD group had a techniques demonstrated
swelling, Absence of periodontal radiographic success rate favorable clinical and
El Meligy et al. DFC group (n = 50) tenderness to ligament space, periapical 100% clinical success rates for of 100% at 12-month radiographic results in
DFC vs. BD◦ SSC 12 months
2019 [87] BD group (n = 50) percussion, fistula, and furcation pathosis, both groups. follow-up, while the DFC primary teeth, after a
abnormal tooth internal resorption. group had a success rate 12-month follow-up
mobility. of 98.1% at 12 months. without any significant
differences.
J. Clin. Med. 2020, 9, 838 14 of 23
Table 3. Cont.
ABS: Ankaferd blood stopper, Ankaferd Health Products Ltd.; BD: Biodentine; CH: Calcium hydroxide; DL: Diode Laser; DFC: diluted formocresol, 20% or one-fifth strength; Buckley’s
Formocresol, Sulton Healthcare; EMP: enamel matrix protein, Emdogain, Straumann; FC: Formocresol; FS: Ferric sulphate; GA: glutaraldehyde, PSK Pharma, Karnataka; GI: glass-ionomer
restorative material, KetacÔ Molar, Easy MixÔ, 3M ESPE; GIC: glass ionomer cement, Vitremer® , 3M ESPE; IRM: Reinforced zinc-eugenol cement, Dentsply.; LLLT: Low Level Laser
Therapy; MTA: Mineral trioxide aggregate; NaOCl: Sodium hypochlorite; PT: Pulpotec, Products Dentaire – PD; SCC: stainless steel crown; ZOE: zinc-eugenol cement; * ProRoot MTA,
Dentsply; ** Ângelus, Londrina; *** MTA-Plus, Avalon Biomed Inc; **** Hemospad, Spad Laboratorie; ◦ Biodentine, Septodont; ◦◦ Biodinâmica Química e Farmacêutica Ltd.a; ◦◦◦ Sultan
Chemists, Englewood; ◦◦◦◦ Pharmadent remedies Pvt. Limited; § Calcium enriched mixture cement (CEM), BioniqueDent; §§ Astringedent – Ultradent Products Inc; §§§ Cresol Formalinan,
GHIMAS S.P.A; # Portland Cement (PC), Votorantim-Cimentos; ## Tempophore (TP), Septodont; ### Vishal Dentocare, Ahmedabad; † Biodinamica Quımica e Farmaceutica Ltd.a;
†† Calxyl® , OCO Präparate GmbH; ††† Ja pan Dental Pharmaceuticals, Co. Ltd.
J. Clin. Med. 2020, 9, 838 15 of 23
In order to ease the reading of the outcomes, the papers were further presented according to the
material that yielded the best result after comparison.
3.4.1. MTA
Almost 65% of the included papers (27/41) demonstrated that MTA provided comparable or
even better results over time when compared to other materials used in the pulpotomy procedures
of deciduous teeth. Specifically, MTA showed better performance than FC after 12 months of
evaluation [67,76,86], with a statistically significant difference reported in two out three of the evaluated
studies [67,86]. Moreover, better results of MTA in comparison to FC were observed after 24 months of
follow-up [55,70,72,85,90], although the differences did not reach a statistical significance except in
one study [55]. The same trend was maintained even after 30 [77] and 42 [78] months of evaluation,
respectively. In two additional studies [66,88], it was reported that FC showed slightly worse results
than MTA at a 24-month evaluation; however, it performed better than other materials assessed during
pulpotomy of primary teeth, such as Pulpotec and Emdogain [88], as well as Portland cement and
enamel matrix protein [66]. On the other hand, Jamali et al. [65] reported a superiority of MTA in respect
to FC after 24 months of evaluation, even though both groups yielded worse results when compared to
3Mixtatin (a combination of simvastatin and 3Mix antibiotic) (78.9% for FC, 90.5% for 3Mixtatin and
88.1% for MTA). However, the differences between groups were not statistically significant.
When solely compared to BD, MTA showed slightly better performances after 12 [56], 18 [61]
and 24 [52] months of assessment, without any statistically significant differences among groups. No
differences between MTA and BD were reported by Juneja et al. [59], evaluating pulpotomy procedures
on primary teeth performed also with FC. However, the authors observed that there were statistically
significant differences between FC and MTA at 12 and 18 months, both clinically and radiographically,
and between FC and BD at 12 and 18 months, only clinically [59]. Accordingly, Guven et al. [57]
demonstrated no differences between BD and MTA groups (total success rates at 24 months were
82.75% BD, 86.2% MTA-P and 93.1% PR-MTA); however, in the same study, primary teeth treated
with FS showed the lowest success rate (75.86%) at a 24-month follow-up, although this was not
statistically significant.
The comparison between MTA and FS yielded not significant differences after 18 [64] and
24 [71] months of evaluation; however, Doyle et al. [73] demonstrated a significantly lower survival
rate for primary teeth treated with eugenol-free FS than MTA, after a follow-up period of 38 months. It
should be noticed that Erdem et al. [71] not only reported the same performance for FS and FC (success
rate of 88% for both groups) at a 24-month follow-up, but also demonstrated a statistically significant
difference between MTA and a group of samples that underwent pulpotomy without use of any pulp
dressing agent (96% vs. 68% after 24 months), suggesting the importance of the traditional pulpotomy
procedure for the VTP of primary molars.
CH seemed to be the most ineffective material for pulpotomies of deciduous teeth and demonstrated
the worst results when compared with MTA [63] after 12 months, and with MTA and FC (MTA 100%,
FC 100%, CH 64%) [74], ProRoot MTA and MTA Angelus [68] and MTA and Portland cement [69] after
24 months of evaluation, respectively. In addition, the differences between CH and all tested materials
were significantly different at all follow-up points.
Finally, the comparison of MTA with other pulpotomy agents, such as calcium-enriched
mixture cement (CEM) [53] and Portland cement [54], provided the same clinical and radiographical
performances of all evaluated materials after a follow-up period of 24 months.
3.4.2. Biodentine
El Meligy et al. [87] clinically and radiographically evaluated 108 primary teeth that underwent
pulpotomy performed with BD or FC. After 12 months, the authors reported a 100% clinical success
rate in both groups and a radiographic success rate of 100% and 98.1% in the BD and FC groups,
respectively, although without any statistically significant difference.
J. Clin. Med. 2020, 9, 838 16 of 23
Three out of the 41 included papers reported the same [60] or even slightly better results [58,62] of
BD in respect to MTA. Specifically, after a follow-up period of 12 months, 39 pulpotomized primary
teeth treated with MTA showed a clinical success rate of 92% (36/39) and a radiographical success rate of
97% (38/39), whereas 39 teeth belonging to the BD group showed a clinical and radiographical success
rate of 97% (38/39) and 95% (37/39), respectively [62]. A 24-month follow-up evaluation revealed that
the clinical success rate of 62 primary molars that underwent pulpotomy was 96.8% (30/31) for both BD
and MTA groups and the radiographic success was 93.6% (29/31) for the BD group and 87.1% (27/31)
for the MTA group [58].
Therefore, although BD showed slightly better clinical results after one year [62] and radiographic
results after two years of follow-up [58], no statistically significant differences were found among groups.
3.4.4. Formocresol
According to the International Agency for Cancer Research, one of the main components of FC,
namely formaldehyde, has been classified as a human carcinogen [93]; due to this reason, FC was not
included as one of the keywords in the search strategy of the present systematic review. However, the
same material is still largely used and was reported in more than half of the included studies (23/41).
Among them, seven papers [75,79,81,82,84,89,91] reported similar or even better results of FC when
compared to other agents used in pulpotomy of primary teeth. Durmus et al. [79] reported a 12-month
clinical success rate of 97% and 92.5% of deciduous teeth pulpotomized and treated with FC and FS,
respectively, as well as comparable radiographical results (87% FC vs.79% FS), without any statistically
significant differences among groups. Moreover, FC and FS provided similar results in pulpotomy
procedures after 12 (clinical success: 96% FC and 95.7% FS; radiographic success: 100% both FC and
FS) and 18 months (clinical success: 96% FC and 87% FS; radiographic success: 100% FC and 91.3% FS)
of evaluation [84]. Markovic et al. [82] compared the 18-month clinical and radiographical success of
pulpotomies performed on 104 primary molars randomly divided into three groups and treated with
FS, FC and CH. FS and FC showed comparable radiographical and clinical success (89.2% and 90.9%,
respectively); on the other hand, the CH group demonstrated lower success than other groups (82.3%),
although this was not statistically significant [82]. Accordingly, comparing pulpotomies with FS, FC
and CH after 12, 24 and 36 months, CH showed the worst results after 24 and 36 months and, even
though the values did not reach statistical significance, the failure rate for the CH group was three
times higher than the FC one [81]. On the other hand, primary teeth treated with FC after pulpotomy
showed slightly better results than the FS group after 12 months of evaluation (96% FC vs. 86% FS),
and vice versa after 24 and 36 months of follow-up (85% FC vs. 86% FS and 72% FC vs. 76% FS,
respectively) [81]. Fernandes et al. [89] reported a significantly better radiographical success rate of
pulpotomy performed with FC compared to CH after 12 (100% FC vs. 50% CH) and 18 months (100%
FC vs. 66.7% CH), demonstrating that CH may not be considered suitable in pulpotomy treatment of
primary molars, even in combination with Low Level Laser Therapy [89]. Similar outcomes were also
J. Clin. Med. 2020, 9, 838 17 of 23
reported by Sonmez et al. [91], who observed 2-year follow-up success rates of 46.1%, 66.6%, 73.3% and
76.9% in 80 primary molars treated with CH, MTA, FS and FC, respectively. Although no statistically
significant differences were detected among groups, CH seemed to be less clinically appropriate than
other evaluated materials. Finally, Noorollahian [75] reported that, after 24 months of evaluation,
primary teeth treated with FC during pulpotomy provided better radiographical results than ones that
underwent MTA, although both groups yielded a 100% clinical success at the same follow-up point.
4. Discussion
VTP aims at preserving pulpal tissue and promoting repair of the mineralized tissue barrier
(dentin bridge) [94]. In addition, the success of this technique would avoid pulpectomy and subsequent
root canal obturation by several materials, that, on turn, could prevent the radicular resorption of the
primary molars and alter the development of the permanent teeth [11].
Since there is a lack of a general consensus regarding an ideal pulp dressing material, the aim of
the present systematic review was to establish a preferred agent to be used in the pulpotomy procedure
of primary teeth affected by deep caries, after raising a PICO question. The evaluation of the included
studies suggested that MTA seemed to be the material of choice after pulpotomies. Although it showed
successful clinical performances over time, the majority of the authors agreed on its drawbacks, such
as high costs, difficult storage and long setting time [4]. Therefore, in some cases, alternative materials
may be used. FC had historically been indicated as a valid option in the pulpotomy procedures of
primary molars; however, the evidence-based scientific literature has already demonstrated its potential
cytotoxicity and carcinogenicity [93]. Due to this reason, FC was not included in the search strategy
of the present systematic review; nevertheless, it is largely used and provides some good clinical
results. Thus, to supply a complete overview on the topic, papers that compared several materials
with FC were included. Seven studies [75,79,81,82,84,89,91] reported better clinical outcomes of FC
than FS. On the other hand, the comparison between FC and MTA [55,66,67,70,72,76–78,85,86,88,90],
yielded a better performance of the latter after 12, 24, 30 and 42 months of evaluation. Accordingly, El
Meligy et al. [87] observed slightly favorable clinical and radiographical outcomes of primary teeth
underwent pulpotomy performed with BD than FC, although no statistically significant.
FS yielded more favorable clinical results when compared to FC in 3/41 studies included in the
present review [80,83,92]. Even though it provided comparable or slightly worse outcomes than
MTA [64,71,73], when the pulpotomized primary molars are going to be replaced by permanent teeth,
FS may be used as a safe alternative [95].
In accordance with the scientific literature [95], the present review confirmed that CH seemed to
be the most ineffective material for pulpotomies of deciduous teeth and demonstrated the worst results
when compared with all tested materials, reaching statistically significant differences at all follow-up
points [52,63,69,74,81,89].
The introduction of calcium-silicate-based cements (such as Biodentine) appears to be promising
for VTP. Indeed, calcium-silicate-based cements seem to play a central role in regenerative endodontics,
inducing pulp regeneration, healing and dentin formation [96]. The present review confirms the
previously reported results [4,15], showing similar outcomes when MTA was compared to BD [52,56–62].
MTA and BD may be classified as bioactive endodontic cements, due to their bioactivity feature, despite
the differences in their chemical compositions [15]. The encouraging clinical properties as well as
biocompatibility of calcium-silicate-based cements indicate that they can be considered as a suitable
alternative to MTA for pulpotomies in primary molars. However, these preliminary results should be
supported by further studies.
Limitations
The main limitation of the present systematic review was the high heterogeneity of the included
studies. Although only randomized clinical comparative studies with at least 12 months of follow-up
were evaluated, the lack of univocal standard procedures made difficult a precise comparison of
J. Clin. Med. 2020, 9, 838 18 of 23
the data. Moreover, the use of several materials composition as well as slightly different outcomes
evaluation provided high variability in the interpretation of the results and could let to a misjudgment
in the Conclusions. Due to this reason, some “confounding” materials reported by several included
studies, such as sodium hypochlorite [84], Er:YAG laser [81], diode laser [79] and low level laser
therapy [89], were excluded in the evaluation of pulpotomy dressing agents.
It should be further considered the high variability given by the type of restoration material used,
although definitive, its interaction with the pulpotomy agent as well as the inconstant time between
the pulpotomy treatment and the physiological exfoliation of the same tooth, that would render very
hard to establish the success of pulpotomy procedure over time.
The quality assessment of the included studies showed an overall high risk of bias, mainly in blinding
of participants and personnel, followed by blinding of outcome assessment. This aspect highlighted the
inadequacies in the published studies, as previously reported by Gopalakrishnan et al. [97]. High quality
study design and standardized clinical and radiographical protocols are needed to prospectively assess
the performances of pulpotomy medicaments used in deciduous teeth.
5. Conclusions
Within the limitation of the present systematic review, MTA seemed to be the gold standard
material in the pulpotomy of primary teeth. Promising results were also provided by BD. On the
contrary, CH should be firmly avoided during pulpotomy procedures. Further RCT studies with
adequate sample sizes and long follow-ups are encouraged to confirm these outcomes.
Author Contributions: Conceptualization, M.B. and F.I.; methodology, G.D.G.; validation, M.B., F.I. and G.D.G.;
investigation, A.S.; data curation, G.D.G.; writing – original draft preparation, F.I.; writing – review & editing, A.P.;
supervision, S.D.C. All authors have read and agreed to the published version of the manuscript.
Funding: The authors deny any sources of funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. US Department of Health and Human Services, National Institute of Dental and Craniofacial Research,
National Institutes of Health. Oral Health in America: A Report of the Surgeon General; U.S. Department of
Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of
Health: Rockville, MD, USA, 2000. Available online: https://www.nidcr.niih.gov/sites/default/files/2017-10/
hck1ocv.%40www.surgeon.fullrpt.pdf (accessed on 2 December 2019).
2. Smaïl-Faugeron, V.; Glenny, A.M.; Courson, F.; Durieux, P.; Muller-Bolla, M.; Fron Chabouis, H. Pulp
treatment for extensive decay in primary teeth. Cochrane Database Syst. Rev. 2018, 5, CD003220.
3. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national
incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries,
1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211–1259.
[CrossRef]
4. Stringhini Junior, E.; Dos Santos, M.G.C.; Oliveira, L.B.; Mercadé, M. MTA and biodentine for primary teeth
pulpotomy: A systematic review and meta-analysis of clinical trials. Clin. Oral Investig. 2019, 23, 1967–1976.
[CrossRef] [PubMed]
5. Bhujel, N.; Duggal, M.S.; Saini, P.; Day, P.F. The effect of premature extraction of primary teeth on the
subsequent need for orthodontic treatment. Eur. Arch. Paediatr. Dent. 2016, 17, 423–434. [CrossRef]
6. American Academy on Pediatric Dentistry; American Academy of Pediatrics. Policy on early childhood
caries (ECC): Classifications, consequences, and preventive strategies. Pediatr. Dent. 2008, 30, 40–43.
7. Dhar, V.; Marghalani, A.A.; Crystal, Y.O.; Kumar, A.; Ritwik, P.; Tulunoglu, O.; Graham, L. Use of vital pulp
therapies in primary teeth with deep caries lesions. Pediatr. Dent. 2017, 39, E146–E159.
8. American Academy on Pediatric Dentistry. Pulp Therapy for Primary and Immature Permanent Teeth.
Pediatr. Dent. 2017, 39, 325–333.
J. Clin. Med. 2020, 9, 838 19 of 23
9. Brizuela, C.; Ormeño, A.; Cabrera, C.; Cabezas, R.; Silva, C.I.; Ramírez, V.; Mercade, M. Direct pulp capping
with calcium hydroxide, mineral trioxide aggregate, and biodentine in permanent young teeth with caries:
A randomized clinical trial. J. Endod. 2017, 43, 1776–1780. [CrossRef]
10. Li, Z.; Cao, L.; Fan, M.; Xu, Q. Direct pulp capping with calcium hydroxide or mineral trioxide aggregate: A
meta-analysis. J. Endod. 2015, 41, 1412–1417. [CrossRef]
11. Smaïl-Faugeron, V.; Porot, A.; Muller-Bolla, M.; Courson, F. Indirect pulp capping versus pulpotomy for
treating deep carious lesions approaching the pulp in primary teeth: A systematic review. Eur. J. Paediatr. Dent.
2016, 17, 107–112.
12. Omar, S. MTA, formocresol, and ferric sulfate have significantly better clinical and radiographic outcomes
than calcium hydroxide and laser therapies in primary molar pulpotomies after 18-24 months. J. Evid. Based
Dent. Pract. 2015, 15, 58–60. [CrossRef] [PubMed]
13. Stringhini Junior, E.; Vitcel, M.E.; Oliveira, L.B. Evidence of pulpotomy in primary teeth comparing MTA,
calcium hydroxide, ferric sulphate, and electrosurgery with formocresol. Eur. Arch. Paediatr. Dent. 2015, 16,
303–312. [CrossRef] [PubMed]
14. Asgary, S.; Shirvani, A.; Fazlyab, M. MTA and ferric sulfate in pulpotomy outcomes of primary molars: A
systematic review and meta-analysis. J. Clin. Pediatr. Dent. 2014, 39, 1–8. [CrossRef] [PubMed]
15. Parirokh, M.; Torabinejad, M.; Dummer, P.M.H. Mineral trioxide aggregate and other bioactive endodontic
cements: An updated overview - part I: Vital pulp therapy. Int. Endod. J. 2018, 51, 177–205. [CrossRef]
[PubMed]
16. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred reporting items for systematic
reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010, 8, 336–341. [CrossRef] [PubMed]
17. Higgins, J.P.T.; Green, S. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0;
The Cochrane Collaboration: 2011. Available online: http://training.cochrane.org/handbook/archive/v5.1/
(accessed on 24 October 2019).
18. Kathal, S.; Gupta, S.; Bhayya, D.P.; Rao, A.; Roy, A.P.; Sabhlok, A. A comparative evaluation of clinical
and radiographic success rate of pulpotomy in primary molars using antioxidant mix and mineral trioxide
aggregate: An in vivo 1-year follow-up study. J. Indian Soc. Pedod. Prev. Dent. 2017, 35, 327–331. [CrossRef]
19. Alsanouni, M.; Bawazir, O.A. A randomized clinical trial of neomta plus in primary molar pulpotomies.
Pediatr. Dent. 2019, 41, 107–111.
20. Pratima, B.; Chandan, G.D.; Nidhi, T.; Nitish, I.; Sankriti, M.; Nagaveni, S.; Shweta, S. Postoperative
assessment of diode laser zinc oxide eugenol and mineral trioxide aggregate pulpotomy procedures in
children: A comparative clinical study. J. Indian Soc. Pedod. Prev. Dent. 2018, 36, 308–314. [CrossRef]
21. Kang, C.M.; Kim, S.H.; Shin, Y.; Lee, H.S.; Lee, J.H.; Kim, G.T.; Song, J.S. A randomized controlled trial of
ProRoot MTA, OrthoMTA and RetroMTA for pulpotomy in primary molars. Oral. Dis. 2015, 21, 785–791.
[CrossRef]
22. Akcay, M.; Sari, S. The effect of sodium hypochlorite application on the success of calcium hydroxide and
mineral trioxide aggregate pulpotomies in primary teeth. Pediatr. Dent. 2014, 36, 316–321.
23. Fernández, C.C.; Martínez, S.S.; Jimeno, F.G.; Lorente Rodríguez, A.I.; Mercadé, M. Clinical and radiographic
outcomes of the use of four dressing materials in pulpotomized primary molars: A randomized clinical trial
with 2-year follow-up. Int. J. Paediatr. Dent. 2013, 23, 400–407. [CrossRef] [PubMed]
24. Liu, H.; Zhou, Q.; Qin, M. Mineral trioxide aggregate versus calcium hydroxide for pulpotomy in primary
molars. Chin. J. Dent. Res. 2011, 14, 121–125.
25. Holan, G.; Eidelman, E.; Fuks, A.B. Long-term evaluation of pulpotomy in primary molars using mineral
trioxide aggregate or formocresol. Pediatr. Dent. 2005, 27, 129–136. [PubMed]
26. Nematollahi, H.; Noorollahian, H.; Bagherian, A.; Yarbakht, M.; Nematollahi, S. Mineral trioxide aggregate
partial pulpotomy versus formocresol pulpotomy: A randomized, split-mouth, controlled clinical trial with
24 months follow-up. Pediatr. Dent. 2018, 40, 184–189. [PubMed]
27. Musale, P.K.; Soni, A.S. Clinical pulpotomy trial of copaifera langsdorffii oil resin versus formocresol and
white mineral trioxide aggregate in primary teeth. Pediatr. Dent. 2016, 38, 5–12. [PubMed]
28. Atasever, G.; Keceli, T.I.; Uysal, S.; Gungor, H.C.; Olmez, S. Primary molar pulpotomies with different
hemorrhage control agents and base materials: A randomized clinical trial. Niger J. Clin. Pract. 2019, 22,
305–312. [PubMed]
J. Clin. Med. 2020, 9, 838 20 of 23
29. Huth, K.C.; Paschos, E.; Hajek-Al-Khatar, N.; Hollweck, R.; Crispin, A.; Hickel, R.; Folwaczny, M. Effectiveness
of 4 pulpotomy techniques–randomized controlled trial. J. Dent. Res. 2005, 84, 1144–1148. [CrossRef]
30. Nguyen, T.D.; Judd, P.L.; Barrett, E.J.; Sidhu, N.; Casas, M.J. Comparison of ferric sulfate combined
mineral trioxide aggregate pulpotomy and zinc oxide eugenol pulpectomy of primary maxillary incisors:
An 18-month randomized, controlled trial. Pediatr. Dent. 2017, 39, 34–38.
31. Saltzman, B.; Sigal, M.; Clokie, C.; Rukavina, J.; Titley, K.; Kulkarni, G.V. Assessment of a novel alternative
to conventional formocresol-zinc oxide eugenol pulpotomy for the treatment of pulpally involved human
primary teeth: Diode laser-mineral trioxide aggregate pulpotomy. Int. J. Paediatr. Dent. 2005, 15, 437–447.
[CrossRef]
32. Grewal, N.; Salhan, R.; Kaur, N.; Patel, H.B. Comparative evaluation of calcium silicate-based dentin
substitute (Biodentine® ) and calcium hydroxide (pulpdent) in the formation of reactive dentin bridge in
regenerative pulpotomy of vital primary teeth: Triple blind, randomized clinical trial. Contemp. Clin. Dent.
2016, 7, 457–463. [CrossRef]
33. Hugar, S.M.; Kukreja, P.; Hugar, S.S.; Gokhale, N.; Assudani, H. Comparative evaluation of clinical and
radiographic success of formocresol, propolis, turmeric gel, and calcium hydroxide on pulpotomized primary
molars: A preliminary study. Int. J. Clin. Pediatr. Dent. 2017, 10, 18–23. [CrossRef] [PubMed]
34. Kalra, M.; Garg, N.; Rallan, M.; Pathivada, L.; Yeluri, R. Comparative evaluation of fresh aloe barbadensis
plant extract and mineral trioxide aggregate as pulpotomy agents in primary molars: A 12-month follow-up
study. Contemp. Clin. Dent. 2017, 8, 106–111.
35. Uloopi, K.S.; Vinay, C.; Ratnaditya, A.; Gopal, A.S.; Mrudula, K.J.; Rao, R.C. Clinical evaluation of low level
diode laser application for primary teeth pulpotomy. J. Clin. Diagn Res. 2016, 10, ZC67–ZC70. [CrossRef]
[PubMed]
36. Yildiz, E.; Tosun, G. Evaluation of formocresol, calcium hydroxide, ferric sulfate, and MTA primary molar
pulpotomies. Eur. J. Dent. 2014, 8, 234–240. [CrossRef] [PubMed]
37. Ansari, G.; Morovati, S.P.; Asgary, S. Evaluation of four pulpotomy techniques in primary molars: A
randomized controlled trial. Iran Endod. J. 2018, 13, 7–12. [PubMed]
38. Gupta, G.; Rana, V.; Srivastava, N.; Chandna, P. Laser pulpotomy-an effective alternative to conventional
techniques: A 12 months clinicoradiographic study. Int. J. Clin. Pediatr. Dent. 2015, 8, 18–21. [PubMed]
39. Cantekin, K.; Gümüş, H. Success rates of ankaferd blood stopper and ferric sulfate as pulpotomy agents in
primary molars. Int. Sch. Res. Notices 2014, 2014, 819605. [CrossRef]
40. Trairatvorakul, C.; Koothiratrakarn, A. Calcium hydroxide partial pulpotomy is an alternative to formocresol
pulpotomy based on a 3-year randomized trial. Int. J. Paediatr. Dent 2012, 22, 382–389. [CrossRef]
41. Zurn, D.; Seale, N.S. Light-cured calcium hydroxide vs. formocresol in human primary molar pulpotomies:
A randomized controlled trial. Pediatr. Dent 2008, 30, 34–41.
42. Percinoto, C.; de Castro, A.M.; Pinto, L.M. Clinical and radiographic evaluation of pulpotomies employing
calcium hydroxide and trioxide mineral aggregate. Gen Dent 2006, 54, 258–261.
43. Ghoniem, N.; Vaidyanathan, V.; Zealand, C.M.; Sushynski, J.M.; Mettlach, S.M.; Botero, T.M.; Majewski, R.F.;
Boynton, J.R.; Hu, J.C. Mineral trioxide aggregate and diluted formocresol pulpotomy: Prospective and
retrospective study outcomes. J. Mich. Dent. Assoc. 2018, 100, 40–65.
44. Biedma Perea, M.; Solano Mendoza, B.; Garcia-Godoy, F.; Mendoza Mendoza, A.; Iglesias-Linares, A. Clinical
and radiographic evaluation of white MTA versus formocresol pulpotomy: A 48-month follow-up study.
Am. J. Dent. 2017, 30, 131–136. [PubMed]
45. Airen, P.; Shigli, A.; Airen, B. Comparative evaluation of formocresol and mineral trioxide aggregate in
pulpotomized primary molars–2 year follow up. J. Clin. Pediatr. Dent. 2012, 37, 143–147. [CrossRef]
[PubMed]
46. Frenkel, G.; Kaufman, A.; Ashkenazi, M. Clinical and radiographic outcomes of pulpotomized primary
molars treated with white or gray mineral trioxide aggregate and ferric sulfate–long-term follow-up. J. Clin.
Pediatr. Dent. 2012, 37, 137–141. [CrossRef] [PubMed]
47. Cardoso-Silva, C.; Barbería, E.; Maroto, M.; García-Godoy, F. Clinical study of Mineral Trioxide Aggregate in
primary molars. Comparison between Grey and White MTA–a long term follow-up (84 months). J. Dent.
2011, 39, 187–193. [CrossRef]
48. Ibricevic, H.; Al-Jame, Q. Ferric sulphate and formocresol in pulpotomy of primary molars: Long term
follow-up study. Eur. J. Paediatr. Dent. 2003, 4, 28–32. [PubMed]
J. Clin. Med. 2020, 9, 838 21 of 23
49. Godhi, B.; Tyagi, R. Success rate of MTA pulpotomy on vital pulp of primary molars: A 3-year observational
study. Int. J. Clin. Pediatr. Dent. 2016, 9, 222–227. [CrossRef]
50. Hugar, S.M.; Deshpande, S.D. Comparative investigation of clinical/radiographical signs of mineral trioxide
aggregate and formocresol on pulpotomized primary molars. Contemp. Clin. Dent. 2010, 1, 146–151.
[CrossRef]
51. Ibricevic, H.; Al-Jame, Q. Ferric sulfate as pulpotomy agent in primary teeth: Twenty month clinical follow-up.
J. Clin. Pediatr. Dent. 2000, 24, 269–272. [CrossRef]
52. Çelik, B.N.; Mutluay, M.S.; Arıkan, V.; Sarı, Ş. The evaluation of MTA and Biodentine as a pulpotomy
materials for carious exposures in primary teeth. Clin. Oral Investig. 2019, 23, 661–666. [CrossRef]
53. Malekafzali, B.; Shekarchi, F.; Asgary, S. Treatment outcomes of pulpotomy in primary molars using two
endodontic biomaterials. A 2-year randomised clinical trial. Eur. J. Paediatr. Dent. 2011, 12, 189–193.
[PubMed]
54. Sakai, V.T.; Moretti, A.B.; Oliveira, T.M.; Fornetti, A.P.; Santos, C.F.; Machado, M.A.; Abdo, R.C. Pulpotomy
of human primary molars with MTA and Portland cement: A randomised controlled trial. Br. Dent. J. 2009,
207, 128–129. [CrossRef] [PubMed]
55. Farsi, N.; Alamoudi, N.; Balto, K.; Mushayt, A. Success of mineral trioxide aggregate in pulpotomized
primary molars. J. Clin. Pediatr. Dent. 2005, 29, 307–311. [CrossRef]
56. Carti, O.; Oznurhan, F. Evaluation and comparison of mineral trioxide aggregate and biodentine in primary
tooth pulpotomy: Clinical and radiographic study. Niger J. Clin. Pract. 2017, 20, 1604–1609. [PubMed]
57. Guven, Y.; Aksakal, S.D.; Avcu, N.; Unsal, G.; Tuna, E.B.; Aktoren, O. Success rates of pulpotomies in primary
molars using calcium silicate-based materials: A randomized control trial. Biomed. Res. Int. 2017, 2017, 4059703.
[CrossRef] [PubMed]
58. Bani, M.; Aktaş, N.; Çınar, Ç.; Odabaş, M.E. The clinical and radiographic success of primary molar pulpotomy
using Biodentine™ and mineral trioxide aggregate: A 24-month randomized clinical trial. Pediatr. Dent.
2017, 39, 284–288.
59. Juneja, P.; Kulkarni, S. Clinical and radiographic comparison of biodentine, mineral trioxide aggregate and
formocresol as pulpotomy agents in primary molars. Eur. Arch. Paediatr. Dent. 2017, 18, 271–278. [CrossRef]
60. Togaru, H.; Muppa, R.; Srinivas, N.; Naveen, K.; Reddy, V.K.; Rebecca, V.C. Clinical and radiographic
evaluation of success of two commercially available pulpotomy agents in primary teeth: An in vivo study. J.
Contemp. Dent. Pract. 2016, 17, 557–563.
61. Rajasekharan, S.; Martens, L.C.; Vandenbulcke, J.; Jacquet, W.; Bottenberg, P.; Cauwels, R.G. Efficacy of three
different pulpotomy agents in primary molars: A randomized control trial. Int. Endod. J. 2017, 50, 215–228.
[CrossRef]
62. Cuadros-Fernández, C.; Lorente Rodríguez, A.I.; Sáez-Martínez, S.; García-Binimelis, J.; About, I.; Mercadé, M.
Short-term treatment outcome of pulpotomies in primary molars using mineral trioxide aggregate and
Biodentine: A randomized clinical trial. Clin. Oral Investig. 2016, 20, 1639–1645. [CrossRef]
63. Silva, L.L.C.E.; Cosme-Silva, L.; Sakai, V.T.; Lopes, C.S.; Silveira, A.P.P.D.; Moretti Neto, R.T.; Gomes-Filho, J.E.;
Oliveira, T.M.; Moretti, A.B.D.S. Comparison between calcium hydroxide mixtures and mineral trioxide
aggregate in primary teeth pulpotomy: A randomized controlled trial. J. Appl. Oral Sci. 2019, 27, e20180030.
[CrossRef] [PubMed]
64. Junqueira, M.A.; Cunha, N.N.O.; Caixeta, F.F.; Marques, N.C.T.; Oliveira, T.M.; Moretti, A.B.D.S.;
Cosme-Silva, L.; Sakai, V.T. Clinical, radiographic and histological evaluation of primary teeth pulpotomy
using MTA and ferric sulfate. Braz. Dent. J. 2018, 29, 159–165. [CrossRef] [PubMed]
65. Jamali, Z.; Alavi, V.; Najafpour, E.; Aminabadi, N.A.; Shirazi, S. Randomized controlled trial of pulpotomy in
primary molars using MTA and formocresol compared to 3Mixtatin: A novel biomaterial. J. Clin. Pediatr. Dent.
2018, 42, 361–366. [CrossRef] [PubMed]
66. Yildirim, C.; Basak, F.; Akgun, O.M.; Polat, G.G.; Altun, C. Clinical and radiographic evaluation of the
effectiveness of formocresol, mineral trioxide aggregate, portland cement, and enamel matrix derivative
in primary teeth pulpotomies: A two year follow-up. J. Clin. Pediatr. Dent. 2016, 40, 14–20. [CrossRef]
[PubMed]
67. Olatosi, O.O.; Sote, E.O.; Orenuga, O.O. Effect of mineral trioxide aggregate and formocresol pulpotomy on
vital primary teeth: A clinical and radiographic study. Niger J. Clin. Pract. 2015, 18, 292–296. [CrossRef]
[PubMed]
J. Clin. Med. 2020, 9, 838 22 of 23
68. Celik, B.; Ataç, A.S.; Cehreli, Z.C.; Uysal, S. A randomized trial of mineral trioxide aggregate cements in
primary tooth pulpotomies. J. Dent. Child (Chic) 2013, 80, 126–132.
69. Oliveira, T.M.; Moretti, A.B.; Sakai, V.T.; Lourenço Neto, N.; Santos, C.F.; Machado, M.A.; Abdo, R.C. Clinical,
radiographic and histologic analysis of the effects of pulp capping materials used in pulpotomies of human
primary teeth. Eur. Arch. Paediatr. Dent 2013, 14, 65–71. [CrossRef]
70. Sushynski, J.M.; Zealand, C.M.; Botero, T.M.; Boynton, J.R.; Majewski, R.F.; Shelburne, C.E.; Hu, J.C.
Comparison of gray mineral trioxide aggregate and diluted formocresol in pulpotomized primary molars: A
6- to 24-month observation. Pediatr. Dent 2012, 34, 120–128.
71. Erdem, A.P.; Guven, Y.; Balli, B.; Ilhan, B.; Sepet, E.; Ulukapi, I.; Aktoren, O. Success rates of mineral trioxide
aggregate, ferric sulfate, and formocresol pulpotomies: A 24-month study. Pediatr. Dent. 2011, 33, 165–170.
72. Ansari, G.; Ranjpour, M. Mineral trioxide aggregate and formocresol pulpotomy of primary teeth: A 2-year
follow-up. Int. Endod. J. 2010, 43, 413–418. [CrossRef]
73. Doyle, T.L.; Casas, M.J.; Kenny, D.J.; Judd, P.L. Mineral trioxide aggregate produces superior outcomes in
vital primary molar pulpotomy. Pediatr. Dent. 2010, 32, 41–47. [PubMed]
74. Moretti, A.B.; Sakai, V.T.; Oliveira, T.M.; Fornetti, A.P.; Santos, C.F.; Machado, M.A.; Abdo, R.C. The
effectiveness of mineral trioxide aggregate, calcium hydroxide and formocresol for pulpotomies in primary
teeth. Int. Endod. J. 2008, 41, 547–555. [CrossRef] [PubMed]
75. Noorollahian, H. Comparison of mineral trioxide aggregate and formocresol as pulp medicaments for
pulpotomies in primary molars. Br. Dent. J. 2008, 204, E20. [CrossRef] [PubMed]
76. Agamy, H.A.; Bakry, N.S.; Mounir, M.M.; Avery, D.R. Comparison of mineral trioxide aggregate and
formocresol as pulp-capping agents in pulpotomized primary teeth. Pediatr. Dent. 2004, 26, 302–309.
77. Eidelman, E.; Holan, G.; Fuks, A.B. Mineral trioxide aggregate vs. formocresol in pulpotomized primary
molars: A preliminary report. Pediatr. Dent. 2001, 23, 15–18.
78. Mettlach, S.E.; Zealand, C.M.; Botero, T.M.; Boynton, J.R.; Majewski, R.F.; Hu, J.C. Comparison of mineral
trioxide aggregate and diluted formocresol in pulpotomized human primary molars: 42-month follow-up
and survival analysis. Pediatr. Dent. 2013, 35, E87–E94.
79. Durmus, B.; Tanboga, I. In vivo evaluation of the treatment outcome of pulpotomy in primary molars using
diode laser, formocresol, and ferric sulphate. Photomed. Laser Surg. 2014, 32, 289–295. [CrossRef]
80. Havale, R.; Anegundi, R.T.; Indushekar, K.; Sudha, P. Clinical and radiographic evaluation of pulpotomies in
primary molars with formocresol, glutaraldehyde and ferric sulphate. Oral Health Dent. Manag. 2013, 12,
24–31.
81. Huth, K.C.; Hajek-Al-Khatar, N.; Wolf, P.; Ilie, N.; Hickel, R.; Paschos, E. Long-term effectiveness of four
pulpotomy techniques: 3-year randomised controlled trial. Clin. Oral Investig. 2012, 16, 1243–1250. [CrossRef]
82. Markovic, D.; Zivojinovic, V.; Vucetic, M. Evaluation of three pulpotomy medicaments in primary teeth.
Eur. J. Paediatr. Dent. 2005, 6, 133–138.
83. Ozmen, B.; Bayrak, S. Comparative evaluation of ankaferd blood stopper, ferric sulfate, and formocresol
as pulpotomy agent in primary teeth: A clinical study. Niger J. Clin. Pract. 2017, 20, 832–838. [CrossRef]
[PubMed]
84. Farsi, D.J.; El-Khodary, H.M.; Farsi, N.M.; El Ashiry, E.A.; Yagmoor, M.A.; Alzain, S.M. Sodium hypochlorite
versus formocresol and ferric sulfate pulpotomies in primary molars: 18-month follow-up. Pediatr. Dent.
2015, 37, 535–540. [PubMed]
85. Jayam, C.; Mitra, M.; Mishra, J.; Bhattacharya, B.; Jana, B. Evaluation and comparison of white mineral
trioxide aggregate and formocresol medicaments in primary tooth pulpotomy: Clinical and radiographic
study. J. Indian Soc. Pedod. Prev. Dent. 2014, 32, 13–18. [CrossRef]
86. Srinivasan, D.; Jayanthi, M. Comparative evaluation of formocresol and mineral trioxide aggregate as
pulpotomy agents in deciduous teeth. Indian J. Dent. Res. 2011, 22, 385–390. [CrossRef] [PubMed]
87. El Meligy, O.A.E.S.; Alamoudi, N.M.; Allazzam, S.M.; El-Housseiny, A.A.M. BiodentineTM versus formocresol
pulpotomy technique in primary molars: A 12-month randomized controlled clinical trial. BMC Oral Health
2019, 19, 3. [CrossRef] [PubMed]
88. Sunitha, B.; Puppala, R.; Kethineni, B.K.; Mallela, M.; Peddi, R.; Tarasingh, P. Clinical and radiographic
evaluation of four different pulpotomy agents in primary molars: A longitudinal study. Int. J. Clin.
Pediatr. Dent. 2017, 10, 240–244.
J. Clin. Med. 2020, 9, 838 23 of 23
89. Fernandes, A.P.; Lourenço Neto, N.; Teixeira Marques, N.C.; Silveira Moretti, A.B.; Sakai, V.T.; Cruvinel
Silva, T.; Andrade Moreira Machado, M.A.; Marchini Oliveira, T. Clinical and radiographic outcomes of
the use of Low-Level Laser Therapy in vital pulp of primary teeth. Int. J. Paediatr. Dent. 2015, 25, 144–150.
[CrossRef]
90. Subramaniam, P.; Konde, S.; Mathew, S.; Sugnani, S. Mineral trioxide aggregate as pulp capping agent for
primary teeth pulpotomy: 2 year follow up study. J. Clin. Pediatr. Dent. 2009, 33, 311–314. [CrossRef]
91. Sonmez, D.; Sari, S.; Cetinbaş, T. A Comparison of four pulpotomy techniques in primary molars: A long-term
follow-up. J. Endod. 2008, 34, 950–955. [CrossRef]
92. Fuks, A.B.; Holan, G.; Davis, J.M.; Eidelman, E. Ferric sulfate versus dilute formocresol in pulpotomized
primary molars: Long-term follow up. Pediatr. Dent. 1997, 19, 327–330.
93. International Agency for Research on Cancer. Pres Release no. 153. 15 June. Available online: www.iarc.fr/
ENG/Press_Releases/archives/pr153a.html (accessed on 16 March 2020).
94. Coll, J.A.; Seale, N.S.; Vargas, K.; Marghalani, A.A.; Al Shamali, S.; Graham, L. Primary tooth vital pulp
therapy: A systematic review and meta-analysis. Pediatr. Dent. 2017, 39, 16–123. [PubMed]
95. Lin, P.Y.; Chen, H.S.; Wang, Y.H.; Tu, Y.K. Primary molar pulpotomy: A systematic review and network
meta-analysis. J. Dent. 2014, 42, 1060–1077. [CrossRef] [PubMed]
96. Gandolfi, M.G.; Spagnuolo, G.; Siboni, F.; Procino, A.; Rivieccio, V.; Pelliccioni, G.A.; Prati, C.; Rengo, S.
Calcium silicate/calcium phosphate biphasic cements for vital pulp therapy: Chemical-physical properties
and human pulp cells response. Clin. Oral. Investig. 2015, 19, 2075–2089. [CrossRef] [PubMed]
97. Gopalakrishnan, V.; Anthonappa, R.; Ekambaram, M.; King, N.M. Qualitative assessment of published
studies on pulpotomy medicaments for primary molar teeth. J. Investig. Clin. Dent. 2019, 10, e12389.
[CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).